The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
about
Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.Matricellular proteins in the trabecular meshwork: review and update.Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure.Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans.Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.Proteomic analysis of meningiomas.Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.The relationship between aminoterminal propeptide of type III procollagen and heart rate variability parameters in heart failure patients: a potential serum marker to evaluate cardiac autonomic control and sudden cardiac death.The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonistsSoluble IgE receptors--elements of the IgE network.Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.Vesicular Galectin-3 levels decrease with donor age and contribute to the reduced osteo-inductive potential of human plasma derived extracellular vesicles.Galectin-3 Is Elevated and Associated With Adverse Outcomes in Patients With Single-Ventricle Fontan Circulation.Detection of galectins during malignant transformation of oral cells.Do galectins play a role in venous thrombosis? a review.Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation.Galectin-3 in cardiac remodeling and heart failure.Risk stratification and short-term prognosis in acute heart failure syndromes: a review of novel biomarkers.Novel biomarkers in chronic heart failure.Personalizing biomarker strategies in heart failure with galectin-3.Does cirrhotic cardiomyopathy exist? 50 years of uncertainty.The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.Heart failure and galectin 3.Myocardial interstitial remodelling in non-ischaemic dilated cardiomyopathy: insights from cardiovascular magnetic resonance.ST2 and Galectin-3: Ready for Prime Time?Novel biomarkers predicting cardiac function after acute myocardial infarction.Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction.Using galectin-3 to reduce heart failure rehospitalization.Labeling galectin-3 for the assessment of myocardial infarction in rats.Plasma galectin-3 predicts clinical outcomes after catheter ablation in persistent atrial fibrillation patients without structural heart disease.DIOL triterpenes block profibrotic effects of angiotensin II and protect from cardiac hypertrophy.How echinoccocosis affects potential cancer markers in plasma: galectin-3, sN-cadherin and sE-cadherin? A preliminary report.Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function.The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively.Prognostic significance of adipocytokines in systolic heart failure patients.Galectin-3 is Persistently Increased in Early Rheumatoid Arthritis (RA) and Associates with Anti-CCP Seropositivity and MRI Bone Lesions, While Early Fibrosis Markers Correlate with Disease Activity.Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
P2860
Q33529398-FFDF4060-B16E-4514-9588-9FA4298440D4Q33820048-7C9838E5-A5F0-4AA1-A01F-C86418EF7789Q34102031-8EF11121-0203-4761-BA5B-E8E1A42339D4Q34122713-75DC9CF9-8B12-4693-B218-66813C35062AQ34528187-ABBEA464-CE7D-488A-9AFB-93CAD09F1508Q35004277-8D4FED71-B92F-4DD8-8855-8E97C3178D31Q35109460-F803FFB5-9C70-4548-B588-5A8D0DFF00B2Q35120924-B7F81949-8FA5-4A09-823F-4CB7E6F23630Q35191679-2A55E6DA-EE89-45F9-B1F9-4836539C362EQ35491143-6EA80871-A5D7-4F34-A2C7-96EB31F0556DQ36052222-005A8012-2945-42B3-88D7-E1B8CFA21F7CQ36439679-B8F8F9D9-B524-4000-9D06-15DE4B8E1BBCQ36522700-80E29497-9CBA-4A53-9D77-D3B78AB90722Q36601648-07D9AEB5-EE63-4B11-A192-AF6B03D5C72DQ36877769-FF6FA3A4-FCBA-4469-BB50-7349B8C2A47FQ37222217-E72839E7-8DB7-4775-A254-744C76F61F9BQ37644081-4535F86A-3A71-452F-A62C-EF8CE5FAF94EQ37662291-D0666988-FD9B-46A8-9FFF-0CB0901986E6Q37738648-B36C46C7-B4CD-42DD-8312-E6C633B0DE0AQ37870921-4D78DAC1-5339-4615-B448-9F399697C600Q37997237-D793544B-6FA6-4D77-8A2D-29C299AFCF61Q38062031-18DF16FD-4500-452E-B3B9-0CE2CEE275E7Q38133308-61254D98-BB6B-4C05-9080-85DE985A484BQ38154222-D26EFE64-1AB8-4EDB-8AD4-A44CAE07A34CQ38194209-F544B029-F82B-4A93-B704-75474AB1A594Q38269044-244889C6-6E17-491A-BCCA-4963E77174E9Q38596113-AC52AD84-84A8-472B-9D38-9E9174AD4EA9Q38816590-5B94BCE8-AE1F-4518-BFA1-9ABA8B0B346BQ38841682-668C5A23-3544-4878-9E91-D5633C069A11Q39127729-D2E7BBB5-09B1-437E-9D93-D980A633804AQ39204234-3D1D3D2F-5C2D-4991-B331-19A64A6BAA9FQ40792117-AAC8CE89-0C6B-4D85-AB7F-77537EEBAD9FQ41002506-4239FCF7-1D7B-4D2A-AB02-2D42EFA22456Q41990989-43A16349-D3EA-40F0-A46F-3950C0089034Q42108524-CC624B70-B79B-478D-BEDF-DCC09CE9C7D3Q42191449-65B311A6-0978-4884-9E5A-2427915AE407Q45129579-5FB7C992-F812-4C40-8288-FED02C72DB35Q46598217-695D2C12-5A39-4E9B-A08A-ED324553DFEAQ47679282-022896F3-4C56-4EF6-BB91-69FDAC3D4299Q48546353-665305AC-55C8-4668-BFE8-C1A2190F4511
P2860
The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The relationship between serum ...... ver in heart failure patients.
@ast
The relationship between serum ...... ver in heart failure patients.
@en
type
label
The relationship between serum ...... ver in heart failure patients.
@ast
The relationship between serum ...... ver in heart failure patients.
@en
prefLabel
The relationship between serum ...... ver in heart failure patients.
@ast
The relationship between serum ...... ver in heart failure patients.
@en
P2093
P50
P1433
P1476
The relationship between serum ...... over in heart failure patients
@en
P2093
Lian-Yu Lin
Lin-Chu Liao
Ming-Fong Chen
Ron-Bin Hsu
Yen-Hung Lin
Yenh-Chen Hsein
P356
10.1016/J.CCA.2009.09.001
P577
2009-09-10T00:00:00Z